biogen idec inc (BIIB:NASDAQ GS)
Douglas Edward Williams Ph.D.
Executive Vice President of Research & Development, Biogen Idec Inc.
|Age||Total Calculated Compensation||This person is connected to 70 board members in 6 different organizations across 14 different industries.|
See Board Relationships
As of Fiscal Year 2013
Dr. Douglas Edward Williams, also known as Doug, Ph.D. has been an Executive Vice President of Research & Development at Biogen Idec Inc. since January 5, 2011. Dr. Williams served as Secretary of Fred Hutchinson Cancer Research Center. Dr. Williams served as the Chief Executive Officer of Zymogenetics Inc. from January 2, 2009 to November 2010. Dr. Williams served as the President of Zymogenetics Inc. from July 2, 2007 to January 2009. Dr. Williams joined ZymoGenetics ...
225 Binney StreetPhone: 617-679-2000
Cambridge, Massachusetts 02142
Board Members Memberships*
Former Chairman of The Board
Former Director and Director of Strategic Development and Health
Former Chief Technology Officer, Executive Vice President and Director
Former Director and Member of Compensation Committee
Former Independent Director, Chairman of Compensation Committee and Member of Corporate Governance & Nominating Committee
Former Director and Member of Audit Committee
Former Chief Executive Officer
University of Massachusetts Lowell
State University of New York at Buffalo Roswell Park Memorial Institute Division
|Lamberto Andreotti||Chief Executive Officer, Director, Member of Executive Committee and Member of Securities Issuance Committee|
Bristol-Myers Squibb Company
|Marc N. Casper||Chief Executive Officer, President, Director, Member of Strategy & Finance Committee and Member of Science & Technology Committee|
Thermo Fisher Scientific, Inc.
|Miles D. White||Chairman, Chief Executive Officer and Chairman of Executive Committee|
|Lars Rebien Sørensen||Chief Executive Officer and Member of Executive Management|
Novo Nordisk A/S
|Yoshihiko Hatanaka||Chief Executive Officer, President and Representative Director|
Astellas Pharma, Inc.
|¥170.0M||Compensation as of Fiscal Year 2013.|